Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology now and into the future.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives, while creating value for society. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
Twitter Feed
-
It is estimated that 50% or more of vertebral fractures are currently under-reported. On #WOD2021, #UCB is delighted to announce that ImageBiopsyLab will bring UCB's innovative identification #BoneBot technology to market. Find out more: https://t.co/
— UCB News (@ucb_news) 20.10.2021 -
It’s #WOD2021 today! In #Osteoporosis the density of bone is reduced, making bones weak, fragile and more likely to break. A #fragilityfracture can be a life-changing event. Speak to your healthcare professional or visit #ucb.com to find out more.
— UCB News (@ucb_news) 20.10.2021 -
At UCB our ambition is to push the boundaries of science and deliver life-changing solutions that can transform healthcare. If you want to evolve today’s amazing science into new medicines, then click here to find out more: https://t.co/wkfuD3MjYK #rdjo
— UCB News (@ucb_news) 19.10.2021
Instagram Feed
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
